| 1/3 | US=5 / Biol/Mol Kessler T, Bayer M, Schwoppe C, Liersch R, Mesters RM, Berdel WE. Compounds in clinical phase III and beyond. In: Liersch R, Berdel WE, Kessler T. Angiogenesis inhibition. New York: Springer, 2010. p. 137-63. (Recent results in cancer research) ISBN 978-3-540-78280-3. ESTUDOS CLINICOS DE FASE III; ANTICORPO ANTI-VEGF; BEVACIZUMABE; AFLIBERCEPT; SORAFENIBE; SUNITINIBE; AXITINIBE; CEDIRANIBE; VANDETANIBE; VATALANIBE; ENDOSTATINA; TALIDOMIDA |
| 2/3 | US=22 / Urologia Motzer RJ. Sunitinib and axitinib in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 151-65. ISBN 978-1-58829-737-2. SUNITINIB; SU11248; AXITINIBE; CARCINOMA DE CELULAS RENAIS; SUTENT; AG-013736 |
| 3/3 | US=120 / Câncer Takahashi TK, Mak MP, Ferrari ACRC, Hoff PMG. Inibidores de tirosina-quinase. In: Hoff PMG. Tratado de oncologia. São Paulo: Atheneu, 2013. p. 805-820. ISBN 85-388-0312-6. FUNCAO E CLASSIFICACAO DA TKS; SERINA TREONINA QUINASES; INIBIDORES TK; INIBIDORES DO EGFR; ERLOTINIBE; GEFITINIBE; LAPATINIBE; AGENTES ANTIANGIOGENICO; SUNITINIBE; SORAFENIBE; PAZOPANIBE; VANDETANIBE; AXITINIBE; AGENTES INIBIDORES DA VIA DO C-KIT; IMATINIBE; DASATINIBE; NILOTINIBE |